US2748128A - Nu-(alpha-cycloalkenylbenzyl) piperazines and method of making - Google Patents

Nu-(alpha-cycloalkenylbenzyl) piperazines and method of making Download PDF

Info

Publication number
US2748128A
US2748128A US446169A US44616954A US2748128A US 2748128 A US2748128 A US 2748128A US 446169 A US446169 A US 446169A US 44616954 A US44616954 A US 44616954A US 2748128 A US2748128 A US 2748128A
Authority
US
United States
Prior art keywords
piperazine
methyl
cycloalkenylbenzyl
piperazines
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US446169A
Inventor
Baltzly Richard
Peter B Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
Burroughs Wellcome Co USA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burroughs Wellcome Co USA filed Critical Burroughs Wellcome Co USA
Priority to US446169A priority Critical patent/US2748128A/en
Application granted granted Critical
Publication of US2748128A publication Critical patent/US2748128A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms

Definitions

  • This invention relates to a family of compounds represented by Formula Iiin which R is a lower alkyl group and R is selected from the class consisting of the A -cyclo hexenyl and the A -cycloheptenyl radicals.
  • the bases and acid addition salts of this formula have marked antihistaminic properties while the mono quaternary salts of Formula II are powerful spasmolytics especially in those cases wherein the phenyl radical has no para substitution.
  • This invention also embraces a method of preparing these compounds.
  • X- may be any convenient anion, preferably derived from the alkyl halide employed.
  • X- is most frequently iodide but for therapeutic purposes chloride, bromide, ethane sulfonate, toluene sulfonate would probably be preferable.
  • chloride, bromide, ethane sulfonate, toluene sulfonate would probably be preferable.
  • these compounds are extremely potent and would seldom be given in doses exceeding 1 to 2 mg., the identity of the anion is actually of no significance.
  • the unsaturated bases of this invention can be reduced catalytically to the corresponding dihydro derivatives which arethe subject of a co-pending application. This reduction may be accomplished by any of the commoncatalysts, preferably however, those not especially addicted to de-benzylation. Adams platinum catalyst, platinized charcoal or Raney nickel are all satisfactory;
  • N-methyl-N'-lu-cyclohex-2-enylbenzyll piperazine 2. N-ethyl-N-[a-cyclohex-Z-enylbenzyl] piperazine. 4. N-methyl-N'-[a-M-cycloheptenylbenzyll piperazine. 5. The method of preparing a compound represented by the formula Ar-CH-N N-Alk -CHCH which comprises reacting a compound of the formula Ar-CH-N N-Alk No references cited.

Description

N-(a-CYCLOALKENYLBENZYL) PIPERAZINES AND METHOD OF MAKING Richard Baltzly, Tuckahoe, and Peter B. Russell, Crestwood, N. Y., assignors to Burroughs Wellcome & Co. (U. S. A.) Iuc., Tuckahoe, N. Y., a corporation of New York No Drawing. Application July 27, 1954, Serial No. 446,169
9 Claims. (Cl. 260-268) This invention relates to a family of compounds represented by Formula Iiin which R is a lower alkyl group and R is selected from the class consisting of the A -cyclo hexenyl and the A -cycloheptenyl radicals. The bases and acid addition salts of this formula have marked antihistaminic properties while the mono quaternary salts of Formula II are powerful spasmolytics especially in those cases wherein the phenyl radical has no para substitution. This is a continuation-in-part of application Serial No. 409,764 filed February 11, 1954.
II /R1 This invention also embraces a method of preparing these compounds. For this purpose we employ the sulfonate, especially the p-toluene sulfonate esters of Formula III (wherein n is 4 or 5) and which are described in a co-pending application.
III
When these tosylates (III) are made to react with bases, the elements of toluenesulfonic acid are eliminated, giving rise to unsaturated Compounds Ia. When the base employed for this elimination is fairly bulky (as sodium or potassium t-butoxide, collidine or 2,6-lutidine) the elimination is unilateral and unaccompanied by detectable side reactions so that Ia is isolated with ease in good yield and in high purity.
nited States Patent 0 ice substantially pure but may be recrystallized from alcohol or alcohol-ether mixtures. In the Formula II, X- may be any convenient anion, preferably derived from the alkyl halide employed. In the earlier stage of operations X- is most frequently iodide but for therapeutic purposes chloride, bromide, ethane sulfonate, toluene sulfonate would probably be preferable. However, since these compounds are extremely potent and would seldom be given in doses exceeding 1 to 2 mg., the identity of the anion is actually of no significance.
Aside from their intrinsic value, the unsaturated bases of this invention can be reduced catalytically to the corresponding dihydro derivatives which arethe subject of a co-pending application. This reduction may be accomplished by any of the commoncatalysts, preferably however, those not especially addicted to de-benzylation. Adams platinum catalyst, platinized charcoal or Raney nickel are all satisfactory;
EXAMPLE 1 N -methyl-N a-cyclohex-Z-enylbenzyl piperazine: By
1 potassium tert. butoxide To a solution of potassium tert. butoxide (from 12 gms. potassium) in tert. butanol (900 cc.) was added the p-toluenesulfonate ester of trans-N-methyl-N-[a-(2-hydroxycyclohexyl)benzyl] piperazine (30 g.). The solution was refluxed for 20 hours and then the tert. butanol removed in vacuo. The residue was dissolved in water and the solution extracted with ether. The basic frac tion was removed from the ether with 2 N hydrochloric acid. The acid solution was basified and the separated base taken up in ether. The ether was removed after washing and drying the solution. The residue wasdistilled to give 15 g. clear oil, B. P; 80 (bath temp.)/ .2 mm. The 'material solidified; recrystallized from pentane it formed needles M. P. 84-.
On catalytic reduction this compound gave N-methyl- N'-[a-cyclohexylbenzyl] piperazine identical with a previously described sample.
On treatment with methyl iodide in acetone the above ".base gave a quaternary salt. After recrystallization from ethanol/ethyl acetate this salt formed prisms M. P. 205-206".
With ethyl iodide the corresponding ethiodide M. P. -181 after recrystallization from ethanol/ethyl acetate resulted.
With isopropyl iodide the corresponding quaternary salt melted at 217220.
With ethyl p-toluenesulfonate a quaternary was formed which melted after recrystallization from ether/ethanol at l07108 with foaming.
EXAMPLE 2 N-methyl-N' [a-cyclohex-Z-enylbenzfl] piperazine: By
heating with 2,6 lutidine EXAMPLE 3 N '-methyl-N I a-cyclohex-Z-enyl-o-chlorobenzyl l piperazine Trans N methyl N [a (hydroxycyclohexyl) o chlorobenzyl] piperazine p-toluene sulfonate (1.3 g.) was added to tert. butoxide (from 0.3 g. potassium) in butanol (20 ml.). The mixture was refluxed for 16 hours in the usual manner and then worked up as previously described. The resin boiled at 95l00 bath temp/0.1 mm. (0.8 g.).
EXAMPLE 4 N-ethyl-N-[a-cyclohex-Z-enylbenzyl] piperazine This compound was prepared by treating the corresponding alcohol trans p-toluenesulfonate (3 g.) with potassium tert. butoxide (from 0.2 g. K) in the usual manner. The product (1.6 g.) boiled at 100 (bath temp.)/0.15 mm. Catalytic reduction of this material gave N-ethyl-N'-[a-cyclohexylbenzyl] piperazine identical with previously described samples.
In acetone solution the unsaturated base reacted with ethyl ethanesulfonate to give N,N-diethyl-N'-la-A -cyclohexenylbenzyl] piperazinium ethane sulfonate.
EXAMPLE 5 N -methyl-N a-d -cycloheptenylbenzyl pi perazi ne The tosylate of 2-a-[N'-methyl-N-piperazino] benzylcycloheptanol (3 g.) was dissolved in 2,6-lutidine (25 ml.) and the solution heated on the steam bath for 36 hours. The mixture was dissolved in pentane and washed 5 or 6 times with water. The pentane solution was dried and the solvent removed. The residue (2 g.) was distilled, the distillate (B. P. 95100 [bath temp.] 0.1 mm.) was a pale yellow oil.
On hydrogenation with a platinum catalyst it gave N- methyl-N-[a-cycloheptylbenzyl] piperazine the ethyl iodide of which was identical with an authentic sample.
The unsaturated base gave with ethyl iodide an ethiodide M. P. 177 (dec.) after recrystallization from acetone-ethyl acetate.
What is claimed is:
1. A compound selected from the class consisting of the free base, acid addition salts and mono-quaternary salts, derived from therapeutically acceptable acids, of compounds having the free base formula:
Ar-G H-N N-Alk (C Ha) wherein Ar is a phenyl radical, alk is a lower alkyl radical and n is an integer from 34.
2. N-methyl-N'-lu-cyclohex-2-enylbenzyll piperazine. 3. N-ethyl-N-[a-cyclohex-Z-enylbenzyl] piperazine. 4. N-methyl-N'-[a-M-cycloheptenylbenzyll piperazine. 5. The method of preparing a compound represented by the formula Ar-CH-N N-Alk -CHCH which comprises reacting a compound of the formula Ar-CH-N N-Alk No references cited.

Claims (1)

1. A COMPOUND SLECTED FROM THE CLASS CONSISTING OF THE FREE BASE, ACID ADDITION SALTS AND MONO-QUATERNARY SALTS, DERIVED FROM THERAPEUTICALLY ACCEPTABLE ACIDS, OF COMPOUNDS HAVING THE FREE BASE FORMULA:
US446169A 1954-07-27 1954-07-27 Nu-(alpha-cycloalkenylbenzyl) piperazines and method of making Expired - Lifetime US2748128A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US446169A US2748128A (en) 1954-07-27 1954-07-27 Nu-(alpha-cycloalkenylbenzyl) piperazines and method of making

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US446169A US2748128A (en) 1954-07-27 1954-07-27 Nu-(alpha-cycloalkenylbenzyl) piperazines and method of making

Publications (1)

Publication Number Publication Date
US2748128A true US2748128A (en) 1956-05-29

Family

ID=23771568

Family Applications (1)

Application Number Title Priority Date Filing Date
US446169A Expired - Lifetime US2748128A (en) 1954-07-27 1954-07-27 Nu-(alpha-cycloalkenylbenzyl) piperazines and method of making

Country Status (1)

Country Link
US (1) US2748128A (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Similar Documents

Publication Publication Date Title
US2441069A (en) 2-amino-methyl-indenes and their production
US2590125A (en) Quaternary-ammonium alkyl
US2649444A (en) Process for the preparation of amino ketones
US2629719A (en) Aminoalkyl thioxanthene oxides and the production thereof
US2625547A (en) Process of preparing benzhydryl and 9-fluorenyl tertiary aminoalkanoates
US2748128A (en) Nu-(alpha-cycloalkenylbenzyl) piperazines and method of making
US3479346A (en) N-acyl-n- (and n,n-bis-) ((1-piperidyl)-lower-alkyl)amines
US2960507A (en) Piperidine compounds
US3077470A (en) 3-[4-hydroxy-3-(aminomethyl)-phenyl]-4-(4-oxyphenyl)-alkanes and alkenes
US2415786A (en) Unsymmetrically substituted piperazines
US3015657A (en) 1-carbalkoxy-4-(aminoalkanol) piperazines
US2691017A (en) Bis-aminoalkyl carbonate derivatives
US2415785A (en) Unsymmetrically substituted piperazines
US2997473A (en) New 2-substituted piperazine derivatives with central stimulating activity
US2683735A (en) Aromatic esters of basically substituted isocyclyl carbamates
US2543764A (en) Diaralkyl carbinyl esters of dialkylamino alkanoates and the production thereof
US2767186A (en) Quaternary ammonium salts of substi-
US2965641A (en) Derivatives of 1-(2-aminoethyl)-5-alkoxy-4-pyridones
US2830049A (en) Acetylenic tetrahydroisoquinoline derivatives
US3324128A (en) Bis-(phenoxyacetyl)-piperazines
US2742472A (en) Spasmolytic pipergzjnes
US2694706A (en) Alkenylamevoalkanoylphenotfflazine
US2551316A (en) 9-aminoalkyl 9-alkanoyl 9, 10 dihydroanthracenes
US2748127A (en) Nu-[alpha-cyclohexenyl benzyl] piperazines and method of making
US1790096A (en) Tertiary amines containing the 1-amino-2-hydroxypropyl residue